Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGENTA: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07032714Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of mezigdomide and talquetamab in multiple myeloma (MM) (2 cohorts), sponsored by Massachusetts General Hospital. Primary endpoint: Recommended Dose at 1 year. Started Dec 2025; status: recruiting.
02
Drugs
mezigdomidetalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07032714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032714.